2020
Head and neck squamous cell carcinoma
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nature Reviews Disease Primers 2020, 6: 92. PMID: 33243986, PMCID: PMC7944998, DOI: 10.1038/s41572-020-00224-3.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaHuman papillomavirusCell carcinomaOral cavityLarynx cancerAJCC/UICC staging systemEGFR monoclonal antibody cetuximabLate stage HNSCCLeast toxic therapyImmune checkpoint inhibitorsHPV-positive HNSCCTreatment of recurrentHPV-positive diseaseOral cavity cancerUICC staging systemHPV-negative HNSCCPre-malignant lesionsDegree of dysplasiaMonoclonal antibody cetuximabUnresectable diseaseCheckpoint inhibitorsPrimary chemoradiotherapyCytotoxic chemotherapyMost patients
2017
TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma
Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma. Cancer 2017, 123: 1778-1790. PMID: 28295222, PMCID: PMC5419871, DOI: 10.1002/cncr.30570.Peer-Reviewed Original ResearchConceptsHPV-positive HNSCCNeck squamous cell carcinomaDe-escalation therapyHPV-positive HNSCCsMechanisms of HPVRecurrent metastatic diseaseBetter overall survivalSquamous cell carcinomaNuclear factor-κB signalingFactor-κB signalingNew therapeutic strategiesNuclear factor κBHPV vaccineCancer Genome AtlasCurative optionHPV statusMetastatic diseaseOverall survivalCervical cancerPatient survivalSmoking characteristicsCell carcinomaHuman papillomavirusLifelong morbidityClinical trials